Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... Pharmacodynamic monitoring has demonstrated
inhibition of PI-3 kinase activity at doses as low as 1 mg ... progressing patients, as well as clearcut
inhibition of PI-3 kinase activity, even in the early ... where it leads to increased proliferation and
inhibition of apoptosis (programmed cell death). PX-866 has ...
Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis
... seen in the model. These results suggest that
inhibition of the PI-3 kinase pathway might be beneficial in ... where it leads to increased proliferation and
inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged
inhibition of tumor PI-3 kinase signaling following both ...
Telik Reports Preclinical Results at AACR Annual Meeting
... associated with aneuploidy and carcinogenesis.
inhibition of Aurora kinase activity induces growth arrest and apoptosis in cells and leads to tumor-growth
inhibition in xenograft models of human cancer.
Key ... drug candidates showing strong and equipotent
inhibition of Aurora kinase and VEGFR kinase, with IC50s ...
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
... lines indicate that perifosine treatment induced
inhibition of Akt phosphorylation, and decreases of cell ...
Targeting breast cancer stem cells through
inhibition of PI3-K/Akt/B-catenin signaling
Author(s): ... and that targeting of cancer stem cells through
inhibition of this signaling pathway represents a rational ...
Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting
... its collaborators presented results on antisense
inhibition of novel targets that could offer new mechanisms ... new preclinical data showing that antisense
inhibition of STAT5 resulted in potent anti-tumor activity. ... a Marker for Carcinomas" showed that antisense
inhibition of Malat-1 altered the splicing of multiple ....
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
... Lead Oral Candidate Demonstrates Proteasome
inhibition and Anti-Tumor Activity
SOUTH SAN ... resulted in rapid and prolonged dose-dependent
inhibition of the proteasome. Furthermore, significant proteasome
inhibition was achieved at doses well below the ...
Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS
... 2008 issue of the magazine.
Entitled "Efficient
inhibition of the Alzheimer's disease
Beta-secretase by ... Unlike existing approaches for
Beta-secretase
inhibition that do not account for the ... In this instance, by directing
inhibition to the sub-compartment
where the enzyme is ...
FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
... have shown that pharmacological FAS
inhibition is cytotoxic to a
variety of human xenograft ... with published in vitro studies where
inhibition of FAS pathway
activity by at least 20% led to ... new
therapeutic products based on the selective
inhibition of fatty acid
biosynthesis. The Company has the ...
ARIUS presents new findings for anti-cancer antibody programs at AACR
... human pancreatic cancer model
(78.7% tumor growth
inhibition at 2 mg/kg compared to control group). ... effects in an AML tumor model (57%
tumor growth
inhibition at a 10 mg/kg compared to control group). ... Moreover, apoptosis is achieved through
inhibition of the
AKT pathway, commonly believed to be an ...
Celadrin(R) Research Unveiled at Nutrigenomics 2008 Meeting in Paris, France
... was found to exert
strong receptor binding
inhibition using a standard radio binding assay.
"The ... those of the white blood cells coupled with
inhibition of
thromboxane production or receptor
inhibition suggests that Celadrin(R)
influences the ...
Option to Develop Exelixis Compound Exercised By Genentech
... trial and subsequent clinical development.
"MEK
inhibition is an exciting approach to cancer therapy. The ... oral administration of XL518 results in sustained
inhibition of ERK
phosphorylation in multiple preclinical ... in clinical trials, with significantly less MEK
inhibition in the
brain. XL518 shows dose-dependent tumor ...
EntreMed Announces 2008 Corporate and Clinical Program Priorities
... antitumor activity, including tumor growth
inhibition or regression in multiple preclinical models. ... Akt-mTOR signaling pathway, which occurs through
inhibition of the mTOR/rictor branch of the pathway. ... profile, including antiproliferative activity and
inhibition of angiogenesis. ENMD-2076 has demonstrated ...
Replidyne Announces 2007 Fourth Quarter and Full Year Results
... an IND candidate from our DNA
replication
inhibition program. Finally, we will continue to seek ... research programs, primarily its C.
difficile and
inhibition of DNA replication programs offset by ... within the C. difficile and
inhibition of DNA replication
programs. These increases were ...
Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
... mechanistic toxicities in the
liver (where MTP
inhibition causes fatty liver) and other organs. ... but avoids the mechanistic toxicities of MTP
inhibition in the liver
and other organs such as the heart, ... by limiting the uptake of dietary fat
through
inhibition of the triglyceride transport function of MTP in ...
XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
... has a unique ratio of reuptake
inhibition of serotonin versus
norepinephrine, which ... another SNRI with a unique ratio of reuptake
inhibition of
serotonin versus norepinephrine to offer to my ... members of the SNRI class
in its unique ratio of
inhibition reuptake of serotonin versus
norepinephrine ...
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
... alone. Initial responses improved with continued therapy. Potent
inhibition of the proteasome has been observed and the lenalidomide/dexamethasone ... proteasome inhibitors. Carfilzomib produces specific and sustained
inhibition of the proteasome, leading to apoptosis in cancer cells with minimal ...
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
... resistance patterns in neuroblastoma cell lines, highlighting AT-101's
inhibition of Mcl-1, also presented -
MALVERN, Pa., April 21 /PRNewswire/ -- ... Ascenta's small molecule pan-Bcl-2 inhibitor, AT-101, had preferential
inhibition in Mcl-1 predominant lines. They concluded that compounds with activity ...
Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR
... of
prematurity model in mice
Overview: Examined the
inhibition of the VEGF/VEGFR pathway with AMG
273 and the
inhibition of the angiopoietin/Tie2 pathway with AMG 386
Lead author: Estrada ...
Buckyballs could keep water systems flowing
... activities.
"As the concentration of buckyballs increased, so did the
inhibition of respiration," Chae said. "This respiratory
inhibition and anti-attachment suggests that this nanoparticle may be useful as an ...
ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
... exhibits characteristics of an ideal microbicide, including the
inhibition of two early steps in the viral replication pathway as well as its lack of ... but may also possess important therapeutic benefits in the context of the
inhibition of highly drug resistant virus strains," said Dr. Buckheit. "We are ...
AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
... that have potent anti-angiogenic / anti-tumor activity through
inhibition of the action of the Id proteins. The Chairman of the Board of AngioGenex, ... the absence of the Id genes in animals results in a highly significant
inhibition of tumor growth and a reduction in the size of mature tumors. The research ...
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
... targets several
serine proteases including Cathepsin G, an enzyme whose
inhibition may play a
role in neuropathic pain. Proteolix researchers believe that ... proteasome
inhibitors. Carfilzomib produces specific and sustained
inhibition of the
proteasome, leading to apoptosis in cancer cells with minimal ...
RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
... simultaneously optimized for expression in the desired host and to escape
inhibition by siRNA that is targeted to the natural gene.
... simultaneously optimized for expression in the desired host and to escape
inhibition by siRNA that is targeted to the natural gene. DNA2.0 guarantees ...
Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
... patients. These include
receptor-mediated targeting of tumor cells and
inhibition of thymidylate
synthase, a key enzyme involved in cell growth and ... believe that BGC 945 (ONX 0801)
may represent the next era in anti-folate
inhibition and has the potential
to be the first targeted therapy of its class with ...
Oncothyreon announces prioritization plan for development programs
... prostate and melanoma, where it leads to increased
proliferation and
inhibition of apoptosis (programmed cell death). PX-866
has been shown to induce prolonged
inhibition of tumor PI-3 kinase
signaling following both oral and intravenous ...
SuperGen Reports 2008 Second Quarter Financial Results
... causing a reduction in phospho-BAD levels and enhancement of mTOR
inhibition in vitro. SGI-1776 induced significant tumor regression in MV-4-11 ... and mutant JAK2 activity in cancer cell lines, resulting in
inhibition of STAT5 phosphorylation as well as a reduction in Bcl-XL ...
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
... prostate and melanoma, where it leads to increased
proliferation and
inhibition of apoptosis (programmed cell death). PX-866
has been shown to induce prolonged
inhibition of tumor PI-3 kinase
signaling following both oral and intravenous ...
GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
... deep experience in antibacterial research and
has validated efflux pump
inhibition for potentiation of antibacterial
activity, as well as expanding the ... intracellular antibiotic concentrations achieved
through efflux pump
inhibition can increase the potency and pharmacological
barrier against other drug ...
Oncothyreon files investigational new drug application for PX-866 oncology compound
... prostate and melanoma, where it leads to increased
proliferation and
inhibition of apoptosis (programmed cell death). PX-866
has been shown to induce prolonged
inhibition of tumor PI-3 kinase
signaling following both oral and intravenous ...
ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
... (p < 0.05)
after 44 days. The study also demonstrated a dose dependent
inhibition of
tumor growth, with the 400mg/kg dose being the most effective, ... a reduction of inflammation and cancer
cell proliferation through
inhibition of NF-kappaB in prostate cancer and
inhibition of TNF-alpha, and ...
Oncothyreon's PX-478 is effective in preclinical model of human lung cancer
... humans. Treatment with oral PX-478 for five days resulted in
significant
inhibition of tumor growth, marked reduction in lymph nodes
metastases, decreased ... orally in animal models, and has shown
marked tumor regressions and growth
inhibition in model systems across a
range of cancers, including lung, ovarian, ...
Oncothyreon highlights corporate and clinical objectives for 2008
... orally in animal models and has shown
marked tumor regressions and growth
inhibition in such model systems across
a range of cancers, including lung, ovarian, ... types of human cancer. The PI-3-kinase inhibitor
PX-866 induces prolonged
inhibition of tumor PI-3-kinase signaling
following both oral and intravenous ...
Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
... innovative combination. Tekturna HCT incorporates the latest
direct renin
inhibition technology and offers an important new option for
patients who need ... mg tablets.
The long-term potential of Tekturna and direct renin
inhibition is
being studied in an extensive clinical program known as ASPIRE ...
Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
... of Hope.
-- 20050244858 Methods and Compositions for the Specific
inhibition of Gene Expression by Double-Stranded RNA -- 20050277610 Methods and Compositions for the Specific
inhibition of Gene Expression by Double-Stranded RNA About Nastech's RNA-Based ...
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
... recombinant human monoclonal antibody which has shown a
beneficial partial
inhibition of the blood coagulation Factor VIII. Its
long half life of approximately ... a stable
and long-acting inhibition. This indicates well-controlled
inhibition of
Factor VIII activity with low risk of spontaneous bleeding, thus ...
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
... tumors. In
addition, data was presented that demonstrated tumor growth
inhibition of
TPI 287 when delivered orally in subcutaneous mouse xenograft models ... inhibit tumor
cell growth in a number of in vitro cell lines and has shown
inhibition of
human tumor growth in certain animal xenograft models when tested ...
AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
... improved; - An interesting difference to the AEZS-112 profile is the
inhibition of topoisomerase I by compounds 2 and 3. Moreover, compound 2 displayed significant higher potency for topoisomerase II
inhibition than AEZS-112; - In vitro plasma and liver microsomal stability of the ...
Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other Cancers
... CTI. "Many of
the current approaches target blocking the IGF receptor or
inhibition of
post receptor kinases in an attempt to slow or kill tumor cell growth and
are often associated with
inhibition of insulin's important metabolic
functions including maintaining normal ...
Rigel to Present Research Programs at Scientific Conferences
... and invasion of tumor cells. The
data to be presented shows that Axl
inhibition may suppress tumor growth
via multiple mechanisms. Rigel has potent, small ... in Breast Cancer Research
in San Diego, October 17-20, 2007. Selective
inhibition of PLK1 could be important in cancer treatment.
Rigel has discovered a new ...
Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
... -- specific ETA receptor antagonism: ZD4054 targets the ETA receptor.
inhibition of this receptor is thought
to be related to multiple processes that drive ... cancer (HRPC) and bone metastases. (2) Morris, C.D. et al. Specific
inhibition of the endothelin A
receptor with ZD4054: clinical and pre-clinical ...